Vogt B, Frey F J
Dept. of Internal Medicine, University Hospital of Berne, Switzerland.
Scand J Gastroenterol Suppl. 1997;222:100-1. doi: 10.1080/00365521.1997.11720730.
The introduction of lactulose as a new therapeutic agent for treatment of hepatic encephalopathy was a major breakthrough in this field. It was hypothesized that lactulose might prevent postoperative renal impairment after biliary surgery in patients with obstructive jaundice. The presumable mechanism purported was the diminished endotoxinemia by lactulose. Unfortunately, such a reno-protective effect has not been shown conclusively until now in clinical studies. In chronic renal failure lactulose is known to promote fecal excretion of water, sodium, potassium, amonium, urea, creatinine and protons. Thus, lactulose could be useful for the treatment of chronic renal failure. However, compliance to the therapy represents a major problem.
乳果糖作为治疗肝性脑病的一种新治疗剂的引入是该领域的一项重大突破。据推测,乳果糖可能预防梗阻性黄疸患者胆道手术后的术后肾功能损害。据称其可能的机制是乳果糖可减轻内毒素血症。不幸的是,到目前为止,这种肾脏保护作用在临床研究中尚未得到确凿证实。在慢性肾衰竭中,已知乳果糖可促进粪便中水分、钠、钾、铵、尿素、肌酐和质子的排泄。因此,乳果糖可能对慢性肾衰竭的治疗有用。然而,治疗的依从性是一个主要问题。